Catalent, Inc. CTLT’s plans for expansion of its biologics segment are likely to bring the stock back after weak second-quarter comps and reaccelerate growth through 2019, according to Raymond James. The Analyst Michael Baker of Raymond James upgraded Catalent from Market Perform to Outperform and assigned the stock a $48 price target. SourceSideways still holds. $CTLT, Catalent, Inc. / D